Mark Thomas

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study

Derralynn Hughes, Suma P. Shankar, Gere Sunder–Plassmann et al. · Journal of Medical Genetics · 2016 · 386 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Nurse‐controlled analgesia (NCA) following major surgery in 10 000 patients in a children’s hospital

Richard F. Howard, A. Lloyd‐Thomas, Mark Thomas et al. · Pediatric Anesthesia · 2010 · 102 citations

Medicine, Anesthesiology, Surgery +17

Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies

Eva Germovsek, Irja Lutsar, Karin Kipper et al. · Journal of Antimicrobial Chemotherapy · 2018 · 75 citations · Full text

Medicine, Pediatrics, Pharmacology +17

Validation of linked administrative data on end-stage renal failure: application of record linkage to a ‘clinical base population’

Kate Brameld, Mark Thomas, C. D’Arcy J. Holman et al. · Australian and New Zealand Journal of Public Health · 1999 · 67 citations

Computing, Biomedical Informatics, Health Informatics +14

Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase

David G. Warnock, Daniel G. Bichet, Myrl Holida et al. · PLoS ONE · 2015 · 62 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +17